Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma

Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma

Abstract Background Dabrafenib and trametinib combination therapy is approved for the treatment of patients with BRAF V600E positive tumors including melanoma and lung cancer. The effect of BRAF and MEK inhibitors on the immune system is not fully understood although a number of case reports indicat...

Full description

Bibliographic Details
Main Authors: Anastasios Dimou, Gregory Barron, Daniel T. Merrick, Jason Kolfenbach, Robert C. Doebele
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cancer
Subjects:
MAPK
Autoimmune side effects
MEK inhibitor
Pyrexia
P-ANCA
Online Access:http://link.springer.com/article/10.1186/s12885-020-6661-6

Internet

http://link.springer.com/article/10.1186/s12885-020-6661-6

Similar Items